Aurora Investment Counsel Has $1.54 Million Stock Position in Cencora, Inc. (NYSE:COR)

Aurora Investment Counsel boosted its holdings in Cencora, Inc. (NYSE:COR) by 1.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,836 shares of the company’s stock after buying an additional 108 shares during the quarter. Aurora Investment Counsel’s holdings in Cencora were worth $1,540,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Kingswood Wealth Advisors LLC acquired a new stake in shares of Cencora in the 2nd quarter valued at approximately $655,000. TD Asset Management Inc acquired a new stake in Cencora in the first quarter valued at approximately $95,313,000. LSV Asset Management bought a new stake in shares of Cencora during the first quarter worth $3,579,000. Cairn Investment Group Inc. acquired a new position in shares of Cencora during the first quarter worth $2,294,000. Finally, Lake Street Advisors Group LLC acquired a new position in shares of Cencora during the first quarter worth $836,000. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In other news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, EVP Silvana Battaglia sold 1,473 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven H. Collis sold 10,755 shares of the business’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the transaction, the chief executive officer now owns 285,088 shares in the company, valued at $63,323,746.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,450,399 shares of company stock valued at $1,070,392,799. 15.80% of the stock is owned by corporate insiders.

Cencora Trading Up 0.1 %

Shares of Cencora stock opened at $225.06 on Tuesday. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. Cencora, Inc. has a 52 week low of $178.21 and a 52 week high of $247.66. The stock has a 50 day moving average price of $234.96 and a two-hundred day moving average price of $232.69. The stock has a market capitalization of $44.89 billion, a PE ratio of 24.62, a price-to-earnings-growth ratio of 1.58 and a beta of 0.44.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. During the same quarter in the previous year, the business posted $2.92 EPS. Cencora’s quarterly revenue was up 10.8% on a year-over-year basis. As a group, equities analysts anticipate that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were issued a $0.51 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.91%. Cencora’s dividend payout ratio is presently 22.32%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on COR shares. Leerink Partners restated an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research report on Thursday, June 27th. Robert W. Baird reduced their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a report on Friday, September 6th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Wells Fargo & Company raised their target price on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Finally, JPMorgan Chase & Co. increased their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $256.67.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.